Track 3 focuses on the rapidly growing global burden of Fatty Liver Disease and Metabolic Syndrome, exploring their close links with obesity, diabetes, cardiovascular disease, and lifestyle factors. This track will highlight the latest advances in pathophysiology, early diagnosis, non-invasive assessment, and emerging therapeutic strategies for NAFLD, MAFLD, and related metabolic liver disorders.
Sessions will feature clinical insights, translational research, innovative treatments, and industry-driven solutions, fostering collaboration between clinicians, researchers, and healthcare innovators. Emphasis will be placed on prevention, precision medicine, and integrated care models to address metabolic liver disease at a global scale.
This track provides an ideal platform for knowledge exchange, investment opportunities, and industry partnerships shaping the future of metabolic and liver health.
Sub Topics: Pathophysiology of Fatty Liver, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Insulin Resistance Mechanisms, Obesity & Liver Disease, Metabolic Syndrome Overview, Dyslipidemia in NAFLD, Hypertension & Liver Health, Type 2 Diabetes & Fatty Liver, Genetic Risk Factors, Epigenetics in NAFLD, Lifestyle Interventions, Diet & Nutrition Strategies, Exercise & Physical Activity, Weight Management Programs, Pharmacologic Therapies, Lipid-Lowering Medications, Anti-Diabetic Drugs, Emerging Therapies, Gut Microbiome & Liver Disease, Hepatic Fibrosis Assessment, Liver Imaging Techniques, Fibrosis Biomarkers, Cirrhosis Risk Management, Liver Transplant Considerations, Cardiovascular Risk in NAFLD, Inflammatory Pathways, Oxidative Stress in Liver Disease, Adipokines & Hormonal Regulation, Nutritional Supplements, Micronutrient Management, Alcohol & NAFLD Interaction, Pediatric Fatty Liver, Geriatric Considerations, Clinical Trials in NAFLD, Patient Education Strategies, Telemedicine in Liver Care, Digital Health Tools, AI in Risk Prediction, Early Detection Protocols, Healthcare Policy & Guidelines, Public Health Strategies, Preventive Care Models, Multidisciplinary Care Teams, Industry Partnerships, Investment in Therapies, Research Innovations, Global Epidemiology, Precision Medicine Approaches
Keynote Points:
Increasing prevalence of hepatitis, fatty liver, and other chronic liver diseases
Strong market potential in antiviral therapies and liver-supportive drugs
Advanced diagnostics: imaging, fibrosis assessment, biomarker testing
Liver transplantation and regenerative medicine as emerging segments
Opportunities for lifestyle, nutrition, and preventive health solutions
Rising demand for education, awareness campaigns, and patient support programs
Collaborations between pharma, biotech, hospitals, and wellness brands
Benefits:
Access to a growing patient population with chronic liver conditions
High ROI potential in innovative therapies, diagnostics, and nutraceuticals
Cross-industry partnership opportunities (healthcare, nutrition, biotech)
Platform for brand visibility and thought leadership in hepatology
Support for preventive care and public health initiatives
Long-term commercial growth through patient education, screening, and management programs
WhatsApp: https://wa.me/+971551792927
Email: info-ucg@utilitarianconferences.com